· 供应链分析

量子点激光投资应优先选择MBE设备供应商如Riber,比下游纯激光公司更早受益于超大规模云厂商资本开支周期。

涉及标的:

中文翻译

如果你想交易超大规模云厂商的资格认证周期……以及像QD Laser(TYO: 6613)这样年内涨幅达226%的量子点激光:IMO最安全的方式是在早期就关注他们未披露的MBE机器供应商,如$ALRIB。然后当他们从资格认证阶段转向批量订单时,再转向纯激光公司。我之前提到过,$MSFT量子的Riber未披露的超大规模云厂商客户。但QD Laser(越来越受欢迎)在量子点项目上也严重依赖Riber。我不看好进入批量生产阶段(比如$AIXA对比实际的批量生产商),因为设备厂商无法捕获下游收入。但如果你想从资本开支研发周期中获益……比如QD Laser吸收资本开支成本(支付给Riber)来建设产能,$ALRIB、$ASML、$AIXA这类公司的财务数据通常会更早反映在资产负债表上,所以你不需要等2-3年才看到生产订单。

英文原文

If you want to trade hyperscaler qualification cycles… And quantum dot like QD Laser (TYO: 6613) up 226% YTD: IMO safest way to do it are their unknown MBE machine suppliers like $ALRIB early on. Then pivot to pure play lasers later when they move from qualification -> volume orders. I mentioned earlier $MSFT quantum was Riber’s undisclosed hyperscaler customer. But QD laser (getting popular) is heavily reliant on Riber too for their quantum dot program. I’m not a fan when it comes time to volume production (eg. $AIXA vs the actual volume producers) since machines don’t capture downstream revenue. But if you want to benefit from capex R&D cycles… eg. QD Laser absorbing capex costs (paying Riber) to build capacity $ALRIB, $ASML, $AIXA type companies usually hits the balance sheet much earlier so you don’t need to wait 2-3 years for production orders.

在 X 上查看原推 ↗